11 results on '"McDanal, Charlene"'
Search Results
2. Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial.
- Author
-
Huang, Ying, Hejazi, Nima S., Blette, Bryan, Carpp, Lindsay N., Benkeser, David, Montefiori, David C., McDermott, Adrian B., Fong, Youyi, Janes, Holly E., Deng, Weiping, Zhou, Honghong, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Flach, Britta, Lin, Bob C., O'Connell, Sarah, McDanal, Charlene, Eaton, Amanda, and Sarzotti-Kelsoe, Marcella
- Subjects
- *
VACCINE effectiveness , *COVID-19 vaccines , *GEOMETRIC distribution , *COVID-19 , *IMMUNOGLOBULIN G , *IMMUNOGLOBULINS - Abstract
The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding antibodies (bAbs), anti-receptor binding domain IgG bAbs, 50% inhibitory dilution neutralizing antibody (nAb) titers, and 80% inhibitory dilution nAb titers were measured at D29 and D57. We assessed these markers as correlates of protection (CoPs) against COVID-19 using stochastic interventional vaccine efficacy (SVE) analysis and principal surrogate (PS) analysis, frameworks not used in our previous COVE immune correlates analyses. By SVE analysis, hypothetical shifts of the D57 Spike IgG distribution from a geometric mean concentration (GMC) of 2737 binding antibody units (BAU)/mL (estimated vaccine efficacy (VE): 92.9% (95% CI: 91.7%, 93.9%)) to 274 BAU/mL or to 27,368 BAU/mL resulted in an overall estimated VE of 84.2% (79.0%, 88.1%) and 97.6% (97.4%, 97.7%), respectively. By binary marker PS analysis of Low and High subgroups (cut-point: 2094 BAU/mL), the ignorance interval (IGI) and estimated uncertainty interval (EUI) for VE were [85%, 90%] and (78%, 93%) for Low compared to [95%, 96%] and (92%, 97%) for High. By continuous marker PS analysis, the IGI and 95% EUI for VE at the 2.5th percentile (519.4 BAU/mL) vs. at the 97.5th percentile (9262.9 BAU/mL) of D57 Spike IgG concentration were [92.6%, 93.4%] and (89.2%, 95.7%) vs. [94.3%, 94.6%] and (89.7%, 97.0%). Results were similar for other D29 and D57 markers. Thus, the SVE and PS analyses additionally support all four markers at both time points as CoPs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.
- Author
-
Pajon, Rolando, Doria-Rose, Nicole A., Montefiori, David C., Shen, Xiaoying, Schmidt, Stephen D, O'Dell, Sijy, McDanal, Charlene, Feng, Wenhong, Tong, Jin, Eaton, Amanda, Maglinao, Maha, Tang, Haili, Manning, Kelly E, Edara, Venkata-Viswanadh, Lai, Lilin, Ellis, Madison, Moore, Kathryn M, Floyd, Katharine, Foster, Stephanie L, and Posavad, Christine M
- Subjects
- *
RESEARCH funding - Published
- 2022
- Full Text
- View/download PDF
4. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
- Author
-
Gilbert, Peter B., Montefiori, David C., McDermott, Adrian B., Fong, Youyi, Benkeser, David, Deng, Weiping, Zhou, Honghong, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Flach, Britta, Lin, Bob C., OÕConnell, Sarah, McDanal, Charlene, Eaton, Amanda, Sarzotti-Kelsoe, Marcella, Lu, Yiwen, Yu, Chenchen, and Borate, Bhavesh
- Subjects
- *
COVID-19 , *VACCINATION , *MESSENGER RNA , *IMMUNOGLOBULINS , *CLINICAL trials - Abstract
In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as correlates of protection. These immune markers were measured at the time of second vaccination and 4 weeks later, with values reported in standardized World Health Organization international units. All markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Vaccine recipients with postvaccination 50% neutralization titers 10, 100, and 1000 had estimated vaccine efficacies of 78% (95% confidence interval, 54 to 89%), 91% (87 to 94%), and 96% (94 to 98%), respectively. These results help define immune marker correlates of protection and may guide approval decisions for messenger RNA (mRNA) COVID-19 vaccines and other COVID-19 vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation.
- Author
-
Huang, Yunda, Borisov, Oleg, Kee, Jia Jin, Carpp, Lindsay N., Wrin, Terri, Cai, Suqin, Sarzotti-Kelsoe, Marcella, McDanal, Charlene, Eaton, Amanda, Pajon, Rolando, Hural, John, Posavad, Christine M., Gill, Katherine, Karuna, Shelly, Corey, Lawrence, McElrath, M. Juliana, Gilbert, Peter B., Petropoulos, Christos J., and Montefiori, David C.
- Subjects
- *
COVID-19 vaccines , *SARS-CoV-2 , *CONVALESCENT plasma , *COVID-19 , *VACCINE effectiveness , *IMMUNOGLOBULINS - Abstract
Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated with vaccine efficacy. In United States government-sponsored phase 3 efficacy trials of COVID-19 vaccines, nAbs are measured by two different validated pseudovirus-based SARS-CoV-2 neutralization assays, with each trial using one of the two assays. Here we describe and compare the nAb titers obtained in the two assays. We observe that one assay consistently yielded higher nAb titers than the other when both assays were performed on the World Health Organization's anti-SARS-CoV-2 immunoglobulin International Standard, COVID-19 convalescent sera, and mRNA-1273 vaccinee sera. To overcome the challenge this difference in readout poses in comparing/combining data from the two assays, we evaluate three calibration approaches and show that readouts from the two assays can be calibrated to a common scale. These results may aid decision-making based on data from these assays for the evaluation and licensure of new or adapted COVID-19 vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms.
- Author
-
Tang, Jun, Jones, Stacey A., Jeffrey, Jerry L., Miranda, Sonia R., Galardi, Cristin M., Irlbeck, David M., Brown, Kevin W., McDanal, Charlene B., and Johns, Brian A.
- Subjects
- *
DRUG development , *ANTI-HIV agents , *GENETIC polymorphisms , *VIROLOGY , *BETULIN - Abstract
A new class of betulin-derived α-keto amides was identified as HIV-1 maturation inhibitors. Through lead optimization, GSK8999 was identified with IC 50 values of 17 nM, 23 nM, 25 nM, and 8 nM for wild type, Q369H, V370A, and T371A respectively. When tested in a panel of 62 HIV-1 isolates covering a diversity of CA-SP1 genotypes including A, AE, B, C, and G using a PBMC based assay, GSK8999 was potent against 57 of 62 isolates demonstrating an improvement over the first generation maturation inhibitor BVM. The data disclosed here also demonstrated that the new α-keto amide GSK8999 has a mechanism of action consistent with inhibition of the proteolytic cleavage of CA-SP1. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase.
- Author
-
Gupta, Kushol, Turkki, Vesa, Sherrill-Mix, Scott, Hwang, Young, Eilers, Grant, Taylor, Louis, McDanal, Charlene, Wang, Ping, Temelkoff, David, Nolte, Robert T., Velthuisen, Emile, Jeffrey, Jerry, Van Duyne, Gregory D., and Bushman, Frederic D.
- Subjects
- *
HIV , *VIRAL replication , *ALLOSTERIC enzymes , *INTEGRASE inhibitors , *DNA - Abstract
The allosteric inhibitors of integrase (termed ALLINIs) interfere with HIV replication by binding to the viral-encoded integrase (IN) protein. Surprisingly, ALLINIs interfere not with DNA integration but with viral particle assembly late during HIV replication. To investigate the ALLINI inhibitory mechanism, we crystallized full-length HIV-1 IN bound to the ALLINI GSK1264 and determined the structure of the complex at 4.4 Å resolution. The structure shows GSK1264 buried between the IN C-terminal domain (CTD) and the catalytic core domain. In the crystal lattice, the interacting domains are contributed by two different dimers so that IN forms an open polymer mediated by inhibitor-bridged contacts; the N-terminal domains do not participate and are structurally disordered. Engineered amino acid substitutions at the inhibitor interface blocked ALLINI-induced multimerization. HIV escape mutants with reduced sensitivity to ALLINIs commonly altered amino acids at or near the inhibitor-bound interface, and these substitutions also diminished IN multimerization. We propose that ALLINIs inhibit particle assembly by stimulating inappropriate polymerization of IN via interactions between the catalytic core domain and the CTD and that understanding the interface involved offers new routes to inhibitor optimization. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. In Vitro and Clinical Investigation of the Relationship Between CCR5 Receptor Occupancy and Anti-HIV Activity of Aplaviroc.
- Author
-
Demarest, James F., Sparks, Sara S., Schell, Kathleen, Shibayama, Shiro, McDanal, Charlene B., Lei Fang, Adkison, Kimberly K., Shachoy-Clark, Anne, and Piscitelli, Stephen C.
- Subjects
- *
HUMAN cell culture , *IMMUNODEFICIENCY , *HIV , *MONOCLONAL antibodies , *PHARMACOKINETICS , *PHARMACODYNAMICS , *ANTIVIRAL agents , *CLINICAL trials - Abstract
Aplaviroc (GW873140) binds specifically to human cellular CC chemokine receptor 5 (CCR5) and demonstrates potent anti-human immunodeficiency virus activity in vitro in the subnanomolar range. In vitro studies show that aplaviroc selectively inhibits the binding of a particular monoclonal antibody, 45531, to CCR5. Based on this observation, a flow cytometry-based assay was developed to determine percentage CCR5 receptor occupancy (RO). CCR5 receptor occupancy was aplaviroc concentration-dependent and related to anti-human immunodeficiency virus activity in vitro. In the clinical setting, CCR5 receptor occupancy in peripheral blood was >98% in all subjects within 2 to 3 hours of dosing, which is consistent with the peak plasma concentrations of drug. Longitudinal analysis in the drug washout period revealed the time to 50% CCR5 receptor occupancy averaged >100 hours, in both human immunodeficiency virus-positive and human immunodeficiency virus-negative subjects, substantially longer than the plasma pharmacokinetic half-life of 3 hours. The duration of CCR5 receptor occupancy appeared to be dose-dependent and associated with antiviral activity as measured by plasma human immunodeficiency virus RNA nadir following 10 days of multiple dose administration. These data demonstrate that the analysis of CCR5 receptor occupancy, in addition to conventional plasma-based pharmacokinetic measures, provides an informative tool to assist in evaluating the pharmacodynamic and antiviral effects of cellular CC chemokine receptor antagonists. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
9. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
- Author
-
Corbett, Kizzmekia S., Nason, Martha C., Flach, Britta, Gagne, Matthew, O’Connell, Sarah, Johnston, Timothy S., Shah, Shruti N., Edara, Venkata Viswanadh, Floyd, Katharine, Lai, Lilin, McDanal, Charlene, Francica, Joseph R., Flynn, Barbara, Wu, Kai, Choi, Angela, Koch, Matthew, Abiona, Olubukola M., Werner, Anne P., Moliva, Juan I., and Andrew, Shayne F.
- Subjects
- *
IMMUNITY , *MESSENGER RNA , *COVID-19 vaccines , *SARS-CoV-2 , *MUCOUS membranes , *VIRAL replication - Abstract
The article offers insight to a study analysing immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.. It mentions that levels of serum and mucosal spike-specific IgG in mRNA-1273- vaccinated nonhuman primatess were inversely correlated with the reduction of viral replication in the upper airway and lower airway after SARS-CoV-2 challenge.
- Published
- 2021
- Full Text
- View/download PDF
10. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
- Author
-
Li, Dapeng, Edwards, Robert J., Manne, Kartik, Martinez, David R., Schäfer, Alexandra, Alam, S. Munir, Wiehe, Kevin, Lu, Xiaozhi, Parks, Robert, Sutherland, Laura L., Oguin III, Thomas H., McDanal, Charlene, Perez, Lautaro G., Mansouri, Katayoun, Gobeil, Sophie M.C., Janowska, Katarzyna, Stalls, Victoria, Kopp, Megan, Cai, Fangping, and Lee, Esther
- Subjects
- *
IMMUNOGLOBULINS , *SARS-CoV-2 , *COVID-19 , *VIRUS diseases , *VIRAL antibodies , *PNEUMONIA - Abstract
SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) or the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-γ (FcγR)-mediated enhancement of virus infection in vitro , while five non-neutralizing NTD antibodies mediated FcγR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Three of 46 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated bronchoalveolar lavage inflammatory cytokines. Thus, while in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo , increased lung inflammation can rarely occur in SARS-CoV-2 antibody-infused macaques. [Display omitted] • RBD or NTD antibodies exhibited infection enhancement in vitro but not in vivo • Neutralizing or infection-enhancing NTD antibodies bound distinct epitopes • In vitro infection-enhancing antibodies protected from SARS-CoV-2 in vivo • Cross-reactive RBD-neutralizing antibodies were protective—most potent DH1047 Convalescent human-derived SARS-CoV-2 RBD and NTD antibodies mediated neutralization as well as infection enhancement in vitro , yet infusion of these antibodies in mice or cynomolgus macaques resulted in suppression of virus replication. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
- Author
-
Korber, Bette, Fischer, Will M., Gnanakaran, Sandrasegaram, Yoon, Hyejin, Theiler, James, Abfalterer, Werner, Hengartner, Nick, Giorgi, Elena E., Bhattacharya, Tanmoy, Foley, Brian, Hastie, Kathryn M., Parker, Matthew D., Partridge, David G., Evans, Cariad M., Freeman, Timothy M., de Silva, Thushan I., McDanal, Charlene, Perez, Lautaro G., Tang, Haili, and Moon-Walker, Alex
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *PANDEMICS , *VIRAL load , *VIRUSES , *POPULATION - Abstract
A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies revealed a recurrent pattern of G614 increase at multiple geographic levels: national, regional, and municipal. The shift occurred even in local epidemics where the original D614 form was well established prior to introduction of the G614 variant. The consistency of this pattern was highly statistically significant, suggesting that the G614 variant may have a fitness advantage. We found that the G614 variant grows to a higher titer as pseudotyped virions. In infected individuals, G614 is associated with lower RT-PCR cycle thresholds, suggestive of higher upper respiratory tract viral loads, but not with increased disease severity. These findings illuminate changes important for a mechanistic understanding of the virus and support continuing surveillance of Spike mutations to aid with development of immunological interventions. • A SARS-CoV-2 variant with Spike G614 has replaced D614 as the dominant pandemic form • The consistent increase of G614 at regional levels may indicate a fitness advantage • G614 is associated with lower RT PCR Cts, suggestive of higher viral loads in patients • The G614 variant grows to higher titers as pseudotyped virions Korber et al. present evidence that there are now more SARS-CoV-2 viruses circulating in the human population globally that have the G614 form of the Spike protein versus the D614 form that was originally identified from the first human cases in Wuhan, China. Follow-up studies show that patients infected with G614 shed more viral nucleic acid compared with those with D614, and G614-bearing viruses show significantly higher infectious titers in vitro than their D614 counterparts. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.